193 related articles for article (PubMed ID: 25544599)
21. Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition.
Hardeman KN; Peng C; Paudel BB; Meyer CT; Luong T; Tyson DR; Young JD; Quaranta V; Fessel JP
Sci Rep; 2017 Feb; 7():42604. PubMed ID: 28205616
[TBL] [Abstract][Full Text] [Related]
22. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.
Liu C; Peng W; Xu C; Lou Y; Zhang M; Wargo JA; Chen JQ; Li HS; Watowich SS; Yang Y; Tompers Frederick D; Cooper ZA; Mbofung RM; Whittington M; Flaherty KT; Woodman SE; Davies MA; Radvanyi LG; Overwijk WW; Lizée G; Hwu P
Clin Cancer Res; 2013 Jan; 19(2):393-403. PubMed ID: 23204132
[TBL] [Abstract][Full Text] [Related]
23. BRAF Gene and Melanoma: Back to the Future.
Ottaviano M; Giunta EF; Tortora M; Curvietto M; Attademo L; Bosso D; Cardalesi C; Rosanova M; De Placido P; Pietroluongo E; Riccio V; Mucci B; Parola S; Vitale MG; Palmieri G; Daniele B; Simeone E; On Behalf Of Scito Youth
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801689
[TBL] [Abstract][Full Text] [Related]
24. Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.
Goodall ML; Wang T; Martin KR; Kortus MG; Kauffman AL; Trent JM; Gately S; MacKeigan JP
Autophagy; 2014 Jun; 10(6):1120-36. PubMed ID: 24879157
[TBL] [Abstract][Full Text] [Related]
25. Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.
Liu D; Liu X; Xing M
Cell Cycle; 2014; 13(2):208-19. PubMed ID: 24200969
[TBL] [Abstract][Full Text] [Related]
26. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Smalley KS; Lioni M; Dalla Palma M; Xiao M; Desai B; Egyhazi S; Hansson J; Wu H; King AJ; Van Belle P; Elder DE; Flaherty KT; Herlyn M; Nathanson KL
Mol Cancer Ther; 2008 Sep; 7(9):2876-83. PubMed ID: 18790768
[TBL] [Abstract][Full Text] [Related]
27.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
28. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
29. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
[TBL] [Abstract][Full Text] [Related]
30. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.
Sharma A; Madhunapantula SV; Gowda R; Berg A; Neves RI; Robertson GP
Am J Pathol; 2013 Apr; 182(4):1151-62. PubMed ID: 23416158
[TBL] [Abstract][Full Text] [Related]
31. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.
Yancovitz M; Litterman A; Yoon J; Ng E; Shapiro RL; Berman RS; Pavlick AC; Darvishian F; Christos P; Mazumdar M; Osman I; Polsky D
PLoS One; 2012; 7(1):e29336. PubMed ID: 22235286
[TBL] [Abstract][Full Text] [Related]
32. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
Kim JH; Ahn JH; Lee M
Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651
[TBL] [Abstract][Full Text] [Related]
33. BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.
Paoluzzi L; Hanniford D; Sokolova E; Osman I; Darvishian F; Wang J; Bradner JE; Hernando E
Cancer Med; 2016 Jun; 5(6):1183-93. PubMed ID: 27169980
[TBL] [Abstract][Full Text] [Related]
34. BRAF as a target for cancer therapy.
Dienstmann R; Tabernero J
Anticancer Agents Med Chem; 2011 Mar; 11(3):285-95. PubMed ID: 21426297
[TBL] [Abstract][Full Text] [Related]
35. Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.
Capaldo BJ; Roller D; Axelrod MJ; Koeppel AF; Petricoin EF; Slingluff CL; Weber MJ; Mackey AJ; Gioeli D; Bekiranov S
PLoS One; 2015; 10(9):e0138210. PubMed ID: 26405815
[TBL] [Abstract][Full Text] [Related]
36. A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy.
Lelliott EJ; Cullinane C; Martin CA; Walker R; Ramsbottom KM; Souza-Fonseca-Guimaraes F; Abuhammad S; Michie J; Kirby L; Young RJ; Slater A; Lau P; Meeth K; Oliaro J; Haynes N; McArthur GA; Sheppard KE
Sci Rep; 2019 Feb; 9(1):1225. PubMed ID: 30718660
[TBL] [Abstract][Full Text] [Related]
37. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in
White MG; Szczepaniak Sloane R; Witt RG; Reuben A; Gaudreau PO; Andrews MC; Feng N; Johnson S; Class CA; Bristow C; Wani K; Hudgens C; Nezi L; Manzo T; De Macedo MP; Hu J; Davis R; Jiang H; Prieto P; Burton E; Hwu P; Tawbi H; Gershenwald J; Lazar AJ; Tetzlaff MT; Overwijk W; Woodman SE; Cooper ZA; Marszalek JR; Davies MA; Heffernan TP; Wargo JA
Oncoimmunology; 2021; 10(1):1992880. PubMed ID: 34777916
[TBL] [Abstract][Full Text] [Related]
38. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Krepler C; Xiao M; Sproesser K; Brafford PA; Shannan B; Beqiri M; Liu Q; Xu W; Garman B; Nathanson KL; Xu X; Karakousis GC; Mills GB; Lu Y; Ahmed TA; Poulikakos PI; Caponigro G; Boehm M; Peters M; Schuchter LM; Weeraratna AT; Herlyn M
Clin Cancer Res; 2016 Apr; 22(7):1592-602. PubMed ID: 26673799
[TBL] [Abstract][Full Text] [Related]
39. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.
Haq R; Yokoyama S; Hawryluk EB; Jönsson GB; Frederick DT; McHenry K; Porter D; Tran TN; Love KT; Langer R; Anderson DG; Garraway LA; Duncan LM; Morton DL; Hoon DS; Wargo JA; Song JS; Fisher DE
Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4321-6. PubMed ID: 23447565
[TBL] [Abstract][Full Text] [Related]
40. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]